title: Chemoembolization of unresectable hepatocellular carcinoma: Decreased             toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol.
abstract: Chemoembolization with lipiodol (TACE) improves survival of selected patients             with unresectable hepatocellular carcinoma (HCC), but results in substantial toxicity.             To improve treatment tolerance, we conducted this phase II study using doxorubicin-loaded             beads (DC Beads®) delivered by selective transcatheter arterial chemoembolization             (DEB-TACE). We compared the results with those obtained with TACE in our historical             controls. Thirty-five patients were recruited with diagnoses of HCC. Patients             received DEB-TACE with doxorubicin loaded on DC Beads. Computed tomography of             the upper abdomen was performed one month after DEB-TACE. Historical controls             were a group of 70 patients with matched characteristics treated with TACE. After             a median follow-up of 14.1 months (range, 6-36 months), 22 patients (63%) had             an objective response. There was a statistically significant decrease in liver             enzymes (p<0.001), lactate dehydrogenase, (p<0.001) in DEB-TACE-treated             patients compared to TACE-treated patients. DEB-TACE with doxorubicin-loaded DC             Beads, a safe and reliable treatment for HCC, leads to decreased toxicity compared             to TACE.
authors.affiliation: Department of Oncology, Civilian Hospital, Avezzano, Italy. frecchia1946@libero.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Recchia
authors.forename: Giovanni
authors.initials: G
authors.lastname: Passalacqua
authors.forename: Pietro
authors.initials: P
authors.lastname: Filauri
authors.forename: Marco
authors.initials: M
authors.lastname: Doddi
authors.forename: Pietro
authors.initials: P
authors.lastname: Boscarato
authors.forename: Giampiero
authors.initials: G
authors.lastname: Candeloro
authors.forename: Stefano
authors.initials: S
authors.lastname: Necozione
authors.forename: Giovambattista
authors.initials: G
authors.lastname: Desideri
authors.forename: Silvio
authors.initials: S
authors.lastname: Rea
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004998:Ethiodized Oil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011859:Radiography; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004998:Ethiodized Oil; D004317:Doxorubicin